

CLAIMS

1. A compound which is:




or



or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 which is:



or a pharmaceutical acceptable salt thereof.

3. A pharmaceutical composition comprising a compound according to claim 1 or claim 2 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

4. A compound according to and as described in claim 1 or claim 2 or a pharmaceutically acceptable salt thereof for use in the treatment of a disease selected from: cancer, cervical intraepithelial neoplasia, monoclonal gammapathy of unknown significance (MGUS), myelodysplastic

syndrome, aplastic anemia, cervical lesions, skin nevi (pre-melanoma), prostatic intraepithleial (intraductal) neoplasia (PIN), Ductal Carcinoma in situ (DCIS), colon polyps and severe hepatitis, cirrhosisbeta haemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia.

5. Use of a compound according to and as described in claim 1 or claim 2 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disease selected from: cancer, cervical intraepithelial neoplasia, monoclonal gammapathy of unknown significance (MGUS), myelodysplastic syndrome, aplastic anemia, cervical lesions, skin nevi (pre-melanoma), prostatic intraepithleial (intraductal) neoplasia (PIN), Ductal Carcinoma in situ (DCIS), colon polyps and severe hepatitis, cirrhosisbeta haemoglobinopathy disordes, sickle cell disease, sickle cell anemia, and beta thalassemia.

6. Use of a compound as described in claim 1 or claim 2 or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or lessening the severity of cancer.

7. A compound according to claim 1 or claim 2 or a pharmaceutically acceptable salt thereof for use in the inhibition of DNMT1 activity in a mammal in need thereof.

8. Use of a compound as described in claim 1 or claim 2 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cancer, wherein the medicament is to be administered with at least one anti-neoplastic agent.

9. The use claim 8, wherein the at least one anti-neoplastic agent is selected from the group consisting of: anti-microtubule agents, platinum coordination complexes, alkylating agents, antibiotic agents, topoisomerase II inhibitors, antimetabolites, topoisomerase I inhibitors, hormones and hormonal analogues, signal transduction pathway inhibitors, non-receptor tyrosine kinase angiogenesis, inhibitors, immunotherapeutic agents, proapoptotic agents, cell cycle signaling inhibitors, proteasome inhibitors, inhibitors of cancer metabolism, anti-PD-L1 agents, PD-1 antagonist, immuno-modulators, STING modulating compounds, CD39 inhibitors, A2a and A2a adenosine antagonists, TLR4 antagonists, antibodies to ICOS, and antibodies to OX40.

10. A pharmaceutical combination comprising:

a) a compound as described in claim 1 or claim 2 or a pharmaceutically acceptable salt thereof; and

b) at least one anti-neoplastic agent.

11. A pharmaceutical combination as claimed in claim 10 for use in the treatment of cancer.

12. A pharmaceutical combination comprising:

a) a compound as described in claim 1 or claim 2 or a pharmaceutically acceptable salt thereof; and

b) at least one agent useful for treating beta haemoglobinopathies.

13. A pharmaceutical combination as claimed in claim 12 for use in the treatment of sickle cell disease.

14. A pharmaceutical combination as claimed in claim 12 for use in the treatment of sickle cell anemia.

15. A pharmaceutical combination as claimed in claim 12 for use in the treatment of beta-thalassemia.

16. A pharmaceutical composition comprising from 0.5 to 1,000 mg of a compound or pharmaceutically acceptable salt thereof as defined in claim 1 or claim 2, and from 0.5 to 1,000 mg of a pharmaceutically acceptable excipient.